On July 18, 2017, the U.S. Food and Drug Administration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/ VEL/VOX) (Vosevi) fixed-dose combination (FDC), an interferon-free, complete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have:
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On July 18, 2017, the U.S. Food and Drug Administration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/ VEL/VOX) (Vosevi) fixed-dose combination (FDC), an interferon-free, complete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have:
• genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing a nonstructural protein 5A (NS5A) inhibitor; and • genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.
Approval was based on an acceptable safety profile and high sustained virological response rates 12 weeks after the end of treatment (SVR12) in two phase 3 clinical trials in subjects previously treated with a direct-acting antiviral (DAA) regimen. In POLARIS-1, 96% of SOF/VEL/VOX-treated subjects achieved SVR12. In POLARIS-4, 98% of SOF/VEL/VOX-treated subjects achieved SVR12. A key and challenging question in evaluating the data was determining the contribution of VOX to SOF/VEL and how this differed depending on the genotype and patient population. In this article, we provide our perspective on the issues considered in making these determinations, especially regarding the POLARIS-4 data in subjects who have previously been treated with a chronic HCV regimen containing sofosbuvir without an NS5A inhibitor. Conclusion: We seek to provide context as to why a broad indication was given for NS5A inhibitor-experienced patients (HCV genotypes 1-6) while the indication for NS5A inhibitor-na€ ıve patients was limited to HCV genotypes 1a and 3 only. (HEPATOLOGY 2018;67:482-491).
C hronic hepatitis C virus (HCV) infection is a serious and life-threatening condition that can lead to cirrhosis and hepatocellular carcinoma (HCC). (1) (2) (3) Recent studies have shown that achievement of sustained virological response (SVR) is associated with halting the progression of liver disease and decreasing the frequency of chronic hepatitis C (CHC) complications, including cirrhosis, hepatic decompensation, HCC, and liver-related mortality. (4, 5) Abbreviations: AEs, adverse events; ASV, asunaprevir; CHC, chronic hepatitis C; DAA, direct-acting antiviral; DCV, daclatasvir; EC 50 , half-maximal effective concentration; ELB, elbasvir; EOT, end-of-treatment; FDA, U.S. Food and Drug Administration; FDC, fixed-dose combination; GRZ, grazoprevir; GT, genotype; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFN, interferon alfa; LDV, ledipasvir; LLOQ, lower limit of quantification; NDA, new drug application; NS5A, nonstructural protein 5A; OMB, ombitasvir; Peg-IFN, pegylated interferon; PrOD, Paritaprevir/ ritonavir, Ombitasvir, Dasabuvir; RAS, resistance-associated substitution; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; SOF/VEL/VOX, sofosbuvir/velpatasvir/voxilaprevir; SVR, sustained virological response; SVR12, sustained virological response rates 12 weeks after the end of treatment; VEL, velpatasvir; VOX, voxilaprevir.
CHC is a global health problem, affecting an estimated 3-5 million people in the United States and 170 million people worldwide. The majority of cases of chronic HCV infection in the United States are HCV genotype 1 (70%-75%, predominately genotype 1a). Approximately 20% are infected with HCV genotype 2 or 3, approximately 5% with HCV genotype 4, and less than 1% with HCV genotype 5 or 6. (6, 7) Treatment of HCV infection has rapidly evolved since the 2011 approvals of the first direct-acting antivirals (DAAs), boceprevir and telaprevir, both nonstructural (NS)3/4A protease inhibitors.
(8,9) These approvals were followed by the 2013 approvals of simeprevir (SIM; NS3/4A protease inhibitors) and sofosbuvir (SOF; NS5B nucleotide analog polymerase inhibitor). (10, 11) Boceprevir, telaprevir, SOF, and SIM required the use of interferon (IFN) and ribavirin (RBV) for treatment of HCV genotype 1. Since 2013, several other IFN-free DAA regimens were approved for genotypes 1-6, many of which have sustained virological response rates 12 weeks after the end of treatment (SVR12) rates in excess of 90% for most genotypes and exceed 95% for certain populations and genotypes. (12) (13) (14) (15) (16) (17) (18) Despite the high efficacy reported in clinical trials for these HCV DAAs, some patients will not achieve an SVR or cure. Patients who were not successfully treated with an NS3/4A protease inhibitor with pegylated IFN (Peg-IFN) and RBV were included in several clinical trials of the currently approved HCV DAAs. These patients can be successfully retreated in some circumstances, as noted in the respective product labeling. (12) (13) (14) (15) (16) (17) Gilead developed voxilaprevir (VOX), an HCV NS3/4A protease inhibitor with activity across HCV genotypes 1-6. VOX is part of a fixeddose combination (FDC) tablet with SOF (approved in 2011) and velpatasvir (VEL; approved in 2016). The FDC tablet containing SOF, VEL, and VOX was recently approved by the U.S. Food and Drug Administration (FDA) with the trade name Vosevi. Part of the development program for Vosevi was designed to evaluate efficacy in DAA-experienced patients. The trials in DAA-experienced patients supported the New Drug Application (NDA) for Vosevi. 
Materials and Methods

DEFINITIONS
Consistent with the FDA's draft Guidance for Industry: Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment, the following definitions were used in the efficacy analyses. (20) End of treatment (EOT) was defined as the end of the prespecified or assigned treatment duration.
ARTICLE INFORMATION:
Relapse was defined as HCV RNA lower limit of quantification (LLOQ) after EOT response among subjects who completed treatment.
On Nonvirological failures are subjects who did not achieve SVR and did not meet any virological failure criteria (e.g., discontinued because of adverse event [AE], lost to follow-up, or subject withdrawal)-in Tables 1, 2 , and 5, and in product labeling, these nonvirological failures are classified as "Other."
POLARIS-1
POLARIS-1 is a randomized, double-blind, placebo-controlled, multicenter trial. The trial population consisted of adult subjects with genotype 1, 2, 3, 4, 5, or 6 HCV infection who previously failed a regimen containing an NS5A inhibitor. Only subjects with HCV genotype 1 were randomized, and randomization was stratified by the presence or absence of compensated cirrhosis. Because of the anticipated limited sample size for subjects with lesscommon genotypes (2, 3, 4, 5, or 6), these subjects were not randomized and all received SOF/VEL/ VOX.
No approved treatment options are currently available for NS5A inhibitor treatment-experienced patients of all HCV genotypes. A placebo control was included primarily for safety comparison for genotype (GT)1 (GT2-6 only received SOF/VEL/VOX). POLARIS-1 was designed to show superiority over an 85% performance goal based on the lower bound of the 95% confidence interval for the observed SVR12 rate in the study exceeding 85%. The 85% *One subject with undetermined genotype achieved SVR12. † Four subjects had GT-1 subtypes other than GT-1a or GT-1b; all 4 subjects achieved SVR12. ‡
The denominator for relapse is the number of subjects with HCV RNA <LLOQ at the EOT assessment. §
Other includes subjects who discontinued because of AE, lost to follow-up, or subject withdrawal.
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benchmark is based on the clinical assessment that SVR12 rates below 85% would not be clinically acceptable given the SVR12 rates for the currently approved HCV DAAs.
POLARIS-4
POLARIS-4 is a randomized, open-label, active controlled trial. The trial population consists of subjects who previously failed a HCV DAA-containing regimen that did not include an NS5A inhibitor. Subjects with genotype 1, 2, or 3 HCV infection were randomized 1:1 to either SOF/VEL/VOX or SOF/VEL. Randomization was stratified by HCV genotype and by the presence or absence of compensated cirrhosis. Because of the anticipated limited sample size for subjects with genotypes 4, 5, or 6, these subjects were not randomized and, if enrolled, would all receive SOF/ VEL/VOX.
A SOF/VEL control arm was included in POLARIS-4 to assess the clinical benefit of SOF/ VEL/VOX versus SOF/VEL in DAA-experienced subjects who have not previously received an NS5A inhibitor. The draft Guidance for Industry: CHC: Developing Direct-Acting Antiviral Agents for Treatment states that if multiple genotypes are included in a single trial, then efficacy analyses should be conducted separately within each genotype. However, for uncommon HCV genotypes (i.e., genotypes 5 and 6) with potentially limited data, collective evidence of efficacy and safety will be assessed to determine the strength of evidence. (20) Subset analyses by genotype were also evaluated to assess the contribution of VOX for each genotype. Gilead designed POLARIS-4 to include two primary efficacy analyses; the SVR12 rate for SOF/VEL/VOX and SOF/VEL groups were each separately compared with the performance goal of 85%.
Results
POLARIS-1
Demographics and baseline characteristics were generally balanced across treatment groups.
(19) Overall, 41% had compensated cirrhosis. Of the 263 subjects treated with SOF/VEL/VOX, the most common preceding NS5A inhibitors were ledipasvir (LDV; 51%), daclatasvir (DCV; 27%), ombitasvir (OMB; 11%), VEL (7%), and elbasvir (ELB; 3%).
Key efficacy findings are summarized in Table 1 . Overall, 96% of subjects achieved SVR12. No subjects in the placebo group achieved SVR12. The presence of baseline NS3 protease inhibitor, NS5A inhibitor, and nucleoside analog NS5B inhibitor resistanceassociated substitutions did not affect the SVR rates. *The denominator for relapse is the number of subjects with HCV RNA <LLOQ at the EOT assessment. † Other includes subjects who discontinued because of AE, lost to follow-up, or subject withdrawal.
Seven subjects (3%) experienced virological failure in POLARIS-1, on treatment (n 5 1) or relapse (n 5 6): 2 subjects with HCV genotype 1a, 4 subjects with HCV genotype 3a, and 1 subject with HCV genotype 4d. All subjects had cirrhosis and all had previous exposure to a SOF-containing regimen. At baseline, 6 of the 7 subjects had NS5A inhibitor resistanceassociated substitutions at either position 30 or 93. At virological failure, all 7 subjects had NS5A resistanceassociated substitutions (RAS), with 4 having newly emergent NS5A RAS on treatment (K24R; L31M/ Y93H; E92K; Y93H) using a sensitivity threshold of 1%. Two subjects had emergent NS3 RAS at the time of virological failure (V36A; Q41K/V55A/R155M) using a sensitivity threshold of 1%, whereas no subjects had nucleotide analog NS5B RAS at the time of virological failure.
POLARIS-4
(19) Overall, 46% had compensated cirrhosis. The majority (85%) of subjects were previously treated with a nucleotide analog NS5B polymerase inhibitor (SOF): 69% had past exposure to sofosbuvir with or without Peg-IFN alfa/RBV or RBV, 15% had past exposure to SOF 1 HCV NS3/4A protease inhibitor (boceprevir, SIM, or telaprevir) with or without Peg-IFN alfa/RBV, and <1% had past exposure to SOF 1 investigational HCV DAA. The remaining 15% of subjects without past nucleotide analog NS5B polymerase inhibitor (SOF) exposure received investigational HCV DAAs or an approved HCV NS3/4A protease inhibitor, with or without Peg-IFN alfa/RBV.
Key efficacy findings are summarized in Table 2 . Overall, 98% of subjects achieved SVR12. Only 1 subject treated with SOF/VEL/VOX experienced virological relapse. The key review issue was the fact that the SVR12 rates for SOF/VEL/VOX compared to SOF/ VEL differed by genotype. Treatment with SOF/ VEL/VOX resulted in numerically higher and clinically meaningful SVR12 rates compared to treatment with SOF/VEL in subjects with HCV genotype 1a (98% vs. 89%) and HCV genotype 3 (96% vs. 85%) infection, but not in HCV genotypes 1b, 2, 4, 5, or 6 ( Table 2 ). Similar to POLARIS-1, the presence of baseline NS3 protease inhibitor, NS5A inhibitor, and nucleoside analog NS5B inhibitor RAS did not affect the SVR rates.
SAFETY: POLARIS-1 AND POLARIS-4
No major safety issues specifically related to SOF or VEL or VOX were identified in the NDA review. In POLARIS-1 and POLARIS-4, headache, fatigue, diarrhea, and nausea were the most common AEs reported. In POLARIS-4, diarrhea (14% vs. 3%) and nausea (10% vs. 3%) occurred more commonly with SOF/VEL/VOX compared to SOF/VEL. 
Discussion
BENEFIT-RISK ASSESSMENT
Each drug in an FDC must contribute to efficacy, otherwise patients are at risk for additional side effects without the potential for benefit. (31) A clinical trial with a factorial design is one approach to evaluating two or more drugs to assess the contribution of each drug in an FDC. For the SOF/VEL/VOX development program, the objective was to evaluate the contribution of VOX to SOF/VEL. Determining the contribution of VOX by genotype for the respective patient populations was our primary efficacy review issue.
POLARIS-1
Published retreatment data are not available for patients with HCV genotypes 2, 4, 5, or 6 infection for whom past treatment with an NS5A inhibitor has failed. Only limited data are available on retreatment of patients with HCV genotype 1 or 3 infection who have previously been treated with an HCV regimen containing an NS5A inhibitor. (18) Table 3 summarizes the different retreatment regimens evaluated in trials for subjects who previously received an NS5A inhibitor, along with the corresponding SVR12 results, and the SVR12 results from POLARIS-1 for comparison. (18, (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) Notably, treatment options can include triple or quadruple DAA regimens with treatment duration ranging from 12 to 24 weeks with the addition of weight-based RBV, unless contraindicated.
Although the evidence is generated across different trials, the SVR12 rate was higher for SOF/VEL/VOX compared with retreatment regimens cited in the literature for genotype 1 and 3 patients. Overall, SVR12 rates ranged from 70% to 71% in HCV genotype 1-infected subjects previously treated with LDV/SOF and who were retreated with LDV/SOF for 12 -24 weeks. In comparison, in POLARIS-1, the SVR12 rate was 97% for HCV genotype 1-infected subjects who previously received an NS5A inhibitor-based regimen. Also, numerically higher SVR12 rates were observed in POLARIS-1 (95%) compared to published data from HCV genotype 3-infected patients who previously received SOF/VEL and who were retreated with SOF/VEL1RBV for 24 weeks (76%).
Although some regimens from the published literature for HCV genotype 1-infected subjects had similar SVR12 rates compared to patients treated with SOF/ VEL/VOX in POLARIS-1, these regimens included either three or four DAAs with RBV and were administered for a longer duration of treatment (i.e., 24 weeks). (18, (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) One trial noted that the SVR12 rates for retreatment with LDV/SOF for 24 weeks were affected by the presence of baseline NS5A RAS (60% with baseline NS5A RAS compared to 100% with no baseline NS5A RAS), (21) whereas in POLARIS-1 SVR12 rates were not impacted by the identified baseline RAS. These differences highlight the benefits of SOF/VEL/VOX, which is an RBV-free, 12-week regimen that is not impacted by baseline RAS encountered in the trial. Despite cross-study comparisons in similar patient populations, the difference in SVR12 rates observed in POLARIS-1 are large enough to support SOF/VEL/VOX as an improvement (over the regimens from the literature) for patients who have previously been treated with an HCV regimen containing an NS5A inhibitor.
Although there were a limited number of subjects with HCV genotypes 2, 4, 5, and 6 enrolled in POLARIS-1, these genotypes had an overall 94% SVR12 (32 of 34) with SVR12 ranging from 91% to 100%, no cases of on-treatment virological failure, and baseline RAS did not affect SVR12 in subjects with HCV genotype 4 ( Table 1) . Additionally, there are a lack of published data for these genotypes in patients previously treated with an NS5A inhibitor. Because SVR12 rates in HCV genotypes 2, 4, 5, and 6 were No available data 100% (6/6) *Based on data that were publically available before the approval of SOF/VEL/VOX. Abbreviations: AASLD, American Association for the Study of Liver Diseases; PrOD, Paritaprevir/ritonavir, Ombitasvir, Dasabuvir.
94%, and SVR12 rates for HCV genotype 3 (considered the "hardest-to-treat" genotype) were also high (95%), it was scientifically justifiable to include HCV genotypes 2, 4, 5, and 6 in the product label for patients previously treated with an NS5A inhibitor. Furthermore, both VEL and VOX demonstrated antiviral activity against laboratory and clinical isolates of HCV genotypes 2, 4, 5, and 6 in cell culture replicons with comparable activity to genotype 1 isolates. (17, 19, 32, 33) Median VOX half-maximal effective concentration (EC 50 ) values were 2.8, 0.52, 1.8, and 2.7 nM against clinical isolates of genotypes 2a, 4a, 5a, and 6a transient replicons compared to 0.5 nM against genotype 1 replicons. (19) In transient replicons containing clinical isolates of genotypes 2a, 2b, 4a, 5a, or 6a, median EC 50 values for VEL were 0.011, 0.002, 0.002, 0.005, and 0.007 nM, respectively, compared to 0.019 and 0.012 nM for genotype 1a and 1b, respectively. (17) Another factor in our decision was the reasonable safety profile demonstrated in both POLARIS-1 and POLARIS-4. The overall safety risks, including drug-drug interaction risks, were acceptable for these patients with limited treatment options. Therefore, we concluded that the benefits of SOF/VEL/VOX outweigh the risks for adults who have HCV genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor.
POLARIS-4
Based on the POLARIS-4 results, an indication was not extended to all HCV genotypes for those previously treated with SOF without an NS5A inhibitor. The SVR12 rates are numerically higher for SOF/ VEL/VOX compared to SOF/VEL in subjects with HCV genotype 1a (98% vs. 89%) and with HCV genotype 3 (96% vs. 85%), thereby demonstrating the added benefit of SOF/VEL/VOX over SOF/VEL only in these genotypes. The additional benefit of SOF/VEL/VOX over SOF/VEL was not shown in adults with HCV genotype 1b, 2, 4, 5, or 6 infection previously treated with SOF without an NS5A inhibitor. For HCV genotype 1b, the SVR12 rates were almost identical (96% and 95%) with no virological failures. For HCV genotype 2, the SVR12 rates were similar (100% and 97%). Therefore, the contribution of VOX in HCV genotypes 1b and 2 was not shown from the available data, and additional direct evidence is needed to support the contribution of VOX before extending the indication to genotypes 1b and 2.
Without comparative data for HCV genotypes 4, 5, and 6 (noting that no data are available for genotype 5 and 6), we are not able to determine whether VOX is needed for these genotypes in DAA-experienced subjects who are NS5A inhibitor treatment-na€ ıve.
Our rationale for defining the POLARIS-4 patient population as having previously been treated with an HCV regimen containing SOF without an NS5A inhibitor in the product labeling is based on the findings that the majority of subjects had failed an SOFcontaining regimen (85%), and the contribution of VOX was not shown in those whose past HCV treatment regimen did not contain SOF, including genotype 1a (Table 4 ). For the subgroup of patients who had been previously treated with a non-SOFcontaining regimen, the SVR12 rates were similar for those receiving SOF/VEL/VOX compared to SOF/ VEL. In contrast, for patients who had been previously treated with an SOF-containing regimen, there was additional benefit for SOF/VEL/VOX over SOF/ VEL in HCV genotypes 1a and 3. The results in the product label are presented in Table 5 .
Because the additional benefit of SOF/VELVOX over SOF/VEL was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with SOF without an NS5A inhibitor, in our view the potential risks outweighed the benefits. Given the potential risks for drug-drug interactions and concerns for the potential for AEs in subjects with moderate or severe hepatic impairment and the unknown risks attributed to increased VOX exposure, the indication was not granted for all HCV genotypes. Abbreviation: n/a, not applicable.
The FDA review focuses on whether the benefits of a product outweigh the risks for the use described in the drug labeling. The discussion below summarizes our benefit-risk assessment focusing on the individual benefits and risks of VOX by the patient population and HCV genotypes studied. VOX is an NS3/4A protease inhibitor, and some drugs within the class, including VOX, are known to have increased exposures in patients with moderate-to-severe hepatic impairment (Child-Pugh B and C). Some other NS3/4A protease inhibitors are either contraindicated or not recommended in these populations because of increased risk of alanine transaminase elevations or risk of hepatic decompensation. These issues are important to consider because often patients can fluctuate between Child-Pugh A and B during treatment and the classification can be influenced by subjective assessments. In the VOX phase 1-3 clinical trials, a safety signal for hepatotoxicity was not observed; however, SOF/VEL/VOX is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) because of the higher exposures of VOX (up to 6-fold in non-HCV-infected subjects); the safety and efficacy have not been established in HCV-infected patients with moderate or severe hepatic impairment. The risk of higher VOX exposures is not known. Additionally, several potentially significant drug interactions can occur with VOX resulting in contraindications, not recommended for use or alteration of dose or regimen recommendations.
Given the potential risks for drug-drug interactions, concerns for use in subjects with moderate or severe hepatic impairment and the unknown risks attributed to increased VOX exposure, and the findings that VOX was not shown to add to the efficacy for certain genotypes in NS5A inhibitor-na€ ıve patients, the indication was not granted for all HCV genotypes. Overall, both the benefit and risk considerations informed our decision as to why the indication for NS5A inhibitor-experienced patients includes HCV genotypes 1-6 whereas the indication for NS5A inhibitor-na€ ıve patients was only limited to HCV genotypes 1a and 3 only.
Summary
The data showed substantial evidence of effectiveness to support approval. (34) Based on the favorable benefit-risk assessment, SOF/VEL/VOX was approved for adults with HCV genotypes 1-6 infection who have previously been treated with an HCV regimen containing an NS5A inhibitor as demonstrated in POLARIS-1. The FDC is only recommended for those with HCV genotypes 1a and 3 infection who have previously been treated with an HCV regimen containing SOF without an NS5A inhibitor, because the benefit of adding VOX to SOF/VEL was not shown in HCV genotypes 1b, 2, 4, 5, or 6 in POLARIS-4. Emerging subpopulations of individuals with CHC viral infection who have failed past DAA therapy now have a new approved treatment option with the FDC of SOF/VEL/VOX. Safety and efficacy in patients without cirrhosis and patients with compensated cirrhosis have been demonstrated in *The denominator for relapse is the number of subjects with HCV RNA <LLOQ at the EOT assessment. † Other includes subjects who discontinued because of adverse event, lost to follow-up, or subject withdrawal.
POLARIS-1 and POLARIS-4 with SVR12 rates ranging from 91% to 100% depending on patient population and HCV genotype. SOF/VEL/VOX is not recommended for patients with moderate-to-severe cirrhosis (Child-Pugh B and C) because of higher exposures of VOX in these patients and because the safety and efficacy have not been established in patients with decompensated cirrhosis. With this new FDC and other approved DAAs in the armamentarium, we are moving even closer to eradicating hepatitis C and its attendant morbidity and mortality.
